Serological identification of fast progressors of structural damage with rheumatoid arthritis

Anne Sofie Siebuhr1*, Anne C Bay-Jensen1, Diana J Leeming1, Adam Plat2, Inger Byrjalsen1, Claus Christiansen3, Désirée van de Heijde4 and Morten A Karsdal1

Abstract

Introduction: Rheumatoid arthritis (RA) patients with structural progression are in most need of immediate treatment to maintain tissue integrity. The serum protein fingerprint, type I collagen degradation mediated by matrix metalloproteinases (MMP)-cleavage (C1M), is a biomarker of tissue destruction. We investigated whether baseline serum C1M levels could identify structural progressors and if the biomarker levels changed during anti-inflammatory treatment with tocilizumab (TCZ).

Methods: The LITHE-biomarker study (NCT00106535, n = 585) was a one-year phase III, double-blind, placebo (PBO)-controlled, parallel group study of TCZ 4 or 8 mg/kg every four weeks, in RA patients on stable doses of methotrexate (MTX). Spearman’s ranked correlation was used to assess the correlation between baseline C1M levels and structural progression at baseline and at weeks 24 and 52. Multivariate regression was performed for delta structural progression. Change in C1M levels were studied as a function of time and treatment.

Results: At baseline, C1M was significantly correlated to C-reactive protein (P <0.0001), visual analog scale pain (P <0.0001), disease activity score28-erythrocyte sedimentation rate (DAS28-ESR) (P <0.0001), joint space narrowing (JSN) (P = 0.0056) and modified total Sharp score (mTSS) (P = 0.0006). Baseline C1M was significantly correlated with delta-JSN at Week 24 (R² = 0.09, P = 0.0001) and at Week 52 (R² = 0.27, P <0.0001), and with delta-mTSS at 24 weeks (R² = 0.006, P = 0.0015) and strongly at 52 weeks (R² = 0.013, P <0.0001) in the PBO group. C1M levels were dose-dependently reduced in the TCZ + MTX group.

Conclusions: Baseline C1M levels correlated with worsening joint structure over one year. Serum C1M levels may enable identification of those RA patients that are in most need of aggressive treatment

Trial registration: ClinicalTrials.gov: NCT00106535

Keywords: Structural progression, Connective tissue degradation, Biochemical marker, Identification of patients

Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and massive tissue destruction in multiple synovial joints. Aggressive treatment for patients whose disease is rapidly progressing (progressors) may preserve joint function. However, it is very difficult using standard technologies to identify progressors. Identification of progressors is also important as most anti-inflammatory treatments are associated with side effects emphasizing that only those who are in most need of aggressive treatment (that is, progressors) should be appropriately treated, which may improve the benefit-risk ratio of these therapies.

In RA, the periarticular bone and cartilage undergo major destructive changes, whereas the altered turnover of the synovial membrane results in an expansion of the synovial membrane. The extracellular matrix (ECM) is the most prominent component of these tissues and the most abundant ECM protein is type I collagen. However, type II collagen is the most abundant protein in cartilage and the most investigated collagen with arthritides. Destruction of the ECM is mediated by enzymatic cleavage by different proteases, though predominantly by matrix metalloproteinases (MMPs). MMPs have been shown to be highly up-regulated with RA [1-3] and the
tissue destruction with specific MMPs elevated with disease is a central player in inflammatory disease, such as RA [3,4]. The action of MMPs on ECM results in the release of small protein 'fingerprints' into the circulation, which may be used as markers of tissue destruction [5,6]. It seems reasonable to hypothesize that connective tissue destruction mediated by MMPs could be associated with disease progression in RA.

Type I collagen can be degraded by several proteinases and in the process yields various products, namely CTX-I, ICTP, PINP and C1M (Figure 1). CTX-I is a measurement of Cathepsin K-mediated destruction of type I collagen and is the standard measure for bone resorption [7]. ICTP is a triple cross-linked carboxyterminal telopeptide of type I collagen generated by MMPs and destroyed by Cathepsin K and, therefore, not related to bone type I collagen [7,8]. Lastly, PINP is widely used as a measure of type I collagen formation in bone [9-12].

We recently developed and validated an enzyme-linked immunosorbent assay (ELISA) using a monoclonal antibody detecting a degradation fragment of the helical domain of type I collagen mediated by MMP-cleavage and destroyed by Cathepsin K (C1M) [13]. This ELISA does not recognize intact type I collagen, other collagens, or the products of other proteinase-mediated collagen degradation. C1M is a product of MMP-2, -9 and -13 cleavage of type I collagen, but not MMP-3, -8 or Cathepsin K cleavage. Therefore, C1M is not a biomarker of hard tissue (that is, bone), but a biomarker of soft tissue destruction, due to the destruction of the fragment by Cathepsin K. Therefore, it represents another pool of type I collagen degradation than PINP, CTX-I and ICTP, namely, exclusively MMP-mediated connective tissue destruction [13].

The aim of the present study was to investigate whether MMP-mediated type I collagen destruction, measured by serum levels of C1M, could be a novel biochemical marker for identification of progressors in RA. We investigated whether baseline levels of serum C1M were correlated with structural status and progression of RA, by measuring change in joint space narrowing, total Sharp score and erosion, in the placebo group of the biomarker study of the LITHE study [14]. We, furthermore, investigated whether serum C1M levels were altered following treatment of RA with an anti-IL-6R monoclonal antibody, tocilizumab (TCZ), in combination with methotrexate (MTX) in the biomarker study in the LITHE study [14,15]. Lastly, we investigated if the change in C1M at four weeks was related to change in one year radiographic measures and if including the standard biomarker (C-reactive protein, CRP) of RA increased the predictive value of C1M.

**Material and methods**

**LITHE study**

The LITHE Biomarker study formed part of the LITHE study (ClinicalTrials.gov: NCT00106535), which was a two-year phase III, double-blind, placebo-controlled, parallel group study of TCZ (4 mg/kg or 8 mg/kg every four weeks) + MTX (10 to 25 mg/week) in patients with moderate to severe active RA with an inadequate response to MTX. RA was diagnosed according to the American College of Rheumatology criteria [16], and had to have lasted for six or more months before entering the study. Moreover, the patients had to have radiographically confirmed joint erosion.

The LITHE Biomarker study included 585 patients followed for the first 52 weeks from baseline. Biomarker patients were equally distributed among the treatment groups; placebo (PBO; n = 199), 4 mg/kg TCZ (TCZ4; n = 200) and 8 mg/kg TCZ (TCZ8; n = 186). Stable non-steroidal anti-inflammatory drugs and corticosteroid (≤10 mg/day prednisone or equivalent) doses were continued throughout the study. Every 4 weeks, patients received an infusion of TCZ 4 mg/kg, 8 mg/kg, or placebo for a total of up to 13 infusions in 52 weeks. Serum for biomarker research was collected following overnight fasting at baseline, at weeks 4, 16, 24 and 52 and non-fasted at Week 2. All samples were stored below -70°C until assay.

 Patients who failed to respond to treatment during the study, that is, experienced ≤20% improvement from...
baseline in both swollen (SJC) and tender joint counts (TJC) at Week 16, could receive blinded rescue therapy from Week 16, and subsequently, 12 weeks later (at Week 28) if there was still ≤20% improvement. First-step rescue patients receiving PBO + MTX at baseline were given 4 mg/kg TCZ + MTX every four weeks from Week 16 to TCZ 4 mg/kg + MTX. Patients receiving 4 mg/kg TCZ + MTX switched to 8 mg/kg + MTX and patients on 8 mg/kg + MTX discontinued treatment. Second-step rescue at Week 28 consisted of TCZ 8 mg/kg + MTX, which were offered through to Week 52 if inadequate response persisted after three doses of first-step rescue therapy. Patients who did not respond after three doses of second-step rescue discontinued treatment. The patients from the PBO + MTX group, who received rescue therapy, were designated escapers. Half of the patients receiving PBO + MTX at baseline were receiving first-step rescue therapy at Week 52. Only six patients were on second step rescue therapy at Week 52 (Figure 2).

Radiographs of hands and feet were obtained at baseline, Week 24 and Week 52. Radiographs were assessed with joint space narrowing (JSN), the total Genant-modified Sharp scoring system (mTSS) [17] and erosion by two independent readers, who were blinded to treatment assignment, chronological order of radiographs and patients’ clinical responses. The average score of the two readers was used in the analysis. The visual analog scale of pain (VAS) and disease activity score-28-erythrocyte sedimentation rate (DAS28-ESR) were assessed at baseline, and at weeks 24 and 52. The self-reported general health was assessed by the Health Assessment Questionnaire (HAQ) at baseline, weeks 24 and 52.

The LITHE study was approved by ethical committees at each participating institution [14]. All patients in the LITHE study provided written informed consent. According to Danish law, it is not required to get ethical approval when measuring biochemical markers in previously collected samples, hence, there was no ethical approval for this particular study of C1M in the LITHE serum samples. The study was conducted according to the Principal of Good Clinical Practice and according to the Declaration of Helsinki.

Biochemical markers
CRP was quantified in patients at baseline, 24 and 52 weeks. C1M was measured in samples taken at baseline and at weeks 2, 4, 16, 24 and 52 using the newly developed C1M ELISA assay (11), which is based on a monoclonal antibody recognizing the fragment GSPGKDGVGRG at position 764 in the mature type I collagen.

Statistics
Summary statistics were used for general demographics, baseline RA characteristics and baseline American College of Rheumatology demographics. Spearman’s ranked correlation was conducted on baseline level of serum C1M, age, body mass index (BMI), disease duration, VAS pain, DAS28-ESR, HAQ, JSN and mTSS. The same correlation test was applied to compare baseline C1M with change in CRP, VAS pain, HAQ, DAS28-ESR, JSN and mTSS at weeks 24 and 52.

Multiple regression analysis was performed on log-transformed data for delta structural progression (JSN, mTSS and erosion score) and C1M, with the cofounders age, BMI, disease duration, baseline CRP and baseline structural status. Changes from baseline in serum C1M levels were studied as a function of time and treatment. Differences between the levels of serum C1M at each time point were compared by two-way ANOVA. The level of change from baseline in C1M for escape patients and non-escape patients in the PBO groups was assessed by two-way ANOVA.

To test if CRP increased the predictive value of C1M to predict progression, high and low levels of C1M and CRP were determined as higher and lower the respective median. This provided four groups: 1: High C1M and high CRP, 2: High C1M and low CRP, 3: Low C1M and high CRP and 4: low C1M and low CRP. Odds ratio for structural progression (JSN and mTSS) were assessed between group 4 and the other groups. The odds ratio for C1M alone was furthermore determined.

Results
Patient demographics at baseline
A total of 585 patients were included at baseline and baseline characteristics are listed in Table 1. Of the 199
was a significant correlation between baseline C1M and delta-mTSS ($\rho = 0.19, P = 0.017$). However, this correlation was stronger when patients receiving rescue treatment ($n = 109$) were excluded from the analysis ($\rho = 0.28, P = 0.0084$). At Week 52 there was an even stronger correlation between delta-mTSS and baseline C1M ($\rho = 0.34, P = 0.0017$) in the patients of the PBO + MTX group not receiving rescue therapy.

Multiple regression analysis

The effect size of C1M was $\beta = 0.34$, $\beta = 1.13$ and $\beta = 0.79$ for the association with the change in structural progression as determined by JSN, mTSS and erosion score at Week 24, respectively. A higher effect size was seen at Week 52 with $\beta = 1.38$, $\beta = 3.40$ and $\beta = 2.01$, respectively. A $\beta$-value illustrates the effect of a variable on another variable, meaning that with a little $\beta$-value the covariates do not have an effect on the predicting value. When $\beta$ is large, the variable has big effect on the predicting value.

The significant association increased when CRP was taken into account at both time points for JSN and mTSS. For erosion score, the significant association was eliminated. When the other possible confounders (age, BMI, disease duration and baseline radiographic score) were included, a slight decrease was detected at both time points with JSN, mTSS and erosion scores (Table 3). Interestingly, the effect of the confounders on mTSS and erosion score at 24 weeks lowered the $\beta$ to below the analysis without the confounders, making the effect of C1M as predicting structural progression less significant.

The overall regression models showed more significance with higher correlation coefficients at Week 52 than Week 24 (Table 3). The model for changes in JSN was strongly correlated with baseline C1M at both 24 and 52 weeks ($P = 0.0029$ and $P < 0.0001$, respectively). The model for mTSS and erosion at 24 weeks was not correlated with C1M ($P = 0.13$ and $P = 0.59$), but strongly correlated at 52 weeks ($P < 0.0001$ and $P = 0.0066$).

Odds ratio for structural progression

We investigated whether a combination of high baseline C1M (>$89.28$ nmol/L) and high baseline CRP (>$1.42$ nmol/L) levels was a stronger predictor of disease progression than C1M alone. Patients with high C1M alone had a significantly higher odds ratio (95% CI) of radiographic progression with both JSN and mTSS than patients with low C1M alone (JSN: 3.15 (1.50 to 6.58), $P = 0.0023$ and mTSS: 2.94 (1.71 to 5.05), $P = 0.0001$). Patients were then categorized according to high or low baseline C1M and high and low CRP determined by the median. Patients having both high C1M and CRP had a significantly higher odds ratio (95% CI) for radiographic progression than patients with both low C1M and CRP.

### Table 1 Baseline characteristics of the Biomarker Study population

| N | 585 |
|---|---|
| % Women | 83% |
| Age (years) | Mean: 52.2, SD: 12.3 |
| BMI (kg/m²) | 27.4, 6.1 |
| Disease duration (years) | 9.4, 8.1 |

| Disease parameters |
|-------------------|
| HAQ | Mean: 1.51, SD: 0.62 |
| VAS pain | Mean: 54.4, SD: 22.1 |
| TJC (n) | 28, 16 |
| SJC (n) | 16, 9 |
| DAS28-ESR | 6.5, 0.93 |
| JSN | Mean: 11.6, SD: 14.4 |
| mTSS | 28.4, 29.6 |
| ERN | 16.6, 16.3 |

| Serum biomarkers |
|-----------------|
| CRP (mg/L) | Mean: 2.13, SD: 2.57 |
| C1M (nmol/L) | Mean: 109, SD: 72.0 |

- **BMI**: Body mass index; **CRP**: C-reactive protein; **DAS28-ESR**: Disease activity score 28-ESR; **ERN**: Erosion score; **HAQ**: Health assessment questionnaire; **JSN**: Joint space narrowing; **mTSS**: Modified total Sharp score; **SJC**: Swollen joint count; **TJC**: Tender joint count; **VAS**: Visual analog scale of pain
Patients with a combination of high and low biomarkers had only slight but not significantly higher odds for radiographic progression than patients with both low C1M and CRP. Of those patients with both high C1M and CRP, 18% and 34% had radiographic progression by JSN and mTSS, respectively. Only 13% and 6% of patients with both low C1M and CRP had radiographic progression read by JSN and mTSS, respectively. Hence, also testing for CRP level increases the odds ratio from 3.15 and 2.94 to 3.61 and 3.55 for JSN and mTSS, respectively.

Dose-dependent response

Patients receiving 4 mg/kg TCZ + MTX had a rapid decrease (in the first two weeks) in C1M levels of 49.6% from baseline. However, this effect disappeared at Week 4 and was not significantly different from the C1M levels seen in the PBO + MTX group (Figure 3A). The C1M fragment was detected at a lower level in the 4 mg/kg TCZ + MTX group at Week 16 (21.6%, \( P > 0.05 \)), 24 (22.4%, \( P < 0.01 \)), and 52 (12.5%, \( P < 0.05 \)). The 8 mg/kg TCZ + MTX group had significantly lower levels of C1M after treatment compared with the PBO + MTX group (Figure 3A). A rapid decrease in C1M was detected at Week 2 (49.2% lower than at baseline, \( P < 0.0001 \)), as was seen in the 4 mg/kg TCZ + MTX group. The level of C1M remained at a significantly lower level in the 8 mg/kg TCZ + MTX than in the PBO group throughout the study (\( P < 0.0001 \)), although C1M levels increased slightly with time.

### Table 2 Univariate correlation between clinical markers and baseline serum C1M

|                      | Baseline (all) | \( \Delta 24 \) weeks (PBO) | \( \Delta 24 \) weeks (PBO w/o escape) | \( \Delta 52 \) weeks (PBO w/o escape) |
|----------------------|----------------|-----------------------------|--------------------------------------|--------------------------------------|
|                      | \( r \) | \( P \) | \( N \) | \( r \) | \( P \) | \( n \) | \( r \) | \( P \) | \( n \) | \( r \) | \( P \) | \( n \) |
| Age                  | -0.06 | ns | 585 | - | - | - | - | - | - | - | - | - |
| BMI                  | 0.01  | ns | 578 | - | - | - | - | - | - | - | - | - |
| Disdur               | -0.01 | ns | 584 | - | - | - | - | - | - | - | - | - |
| CRP                  | 0.80  | <0.0001 | 584 | -0.31 | 0.001 | 112 | -0.31 | 0.0023 | 93 | -0.36 | 0.0007 | 83 |
| VAS pain             | 0.21  | <0.0001 | 578 | -0.08 | ns | 110 | -0.05 | ns | 91 | -0.00 | ns | 83 |
| HAQ                  | 0.21  | <0.0001 | 535 | -0.17 | ns | 98 | -0.15 | ns | 82 | -0.11 | ns | 76 |
| DAS28                | 0.24  | <0.0001 | 573 | 0.09  | ns | 108 | 0.15  | ns | 89 | 0.11  | ns | 77 |
| JSN                  | 0.14  | 0.0056 | 556 | 0.08  | ns | 153 | 0.16  | ns | 90 | 0.21  | 0.055 | 84 |
| mTSS                 | 0.15  | 0.0003 | 556 | 0.19  | 0.017 | 153 | 0.28  | 0.0084 | 90 | 0.34  | 0.0017 | 84 |
| ERN                  | 0.15  | 0.0003 | 556 | 0.19  | 0.019 | 153 | 0.13  | 0.054  | 90 | 0.21  | 0.055  | 84 |

BMI, Body mass index; DisDur, Disease duration; CRP, C-reactive protein; DAS28-ESR, Disease activity score 28-ESR; HAQ, Health assessment questionnaire; JSN, Joint space narrowing; mTSS, modified total Sharp score; PBO, placebo group; VAS pain, Visual analog scale of pain. Spearman rank correlation coefficient, \( r \), \( P \)-values and \( n \) are provided.

### Table 3 Multivariate linear regression analysis of patients in the PBO group, at 24 and 52 weeks

|                      | \( \Delta 24 \) weeks | \( \Delta 52 \) weeks |
|----------------------|-----------------------|-----------------------|
|                      | \( \Delta 24 \) weeks (PBO) | \( \Delta 52 \) weeks (PBO w/o escape) |
| JSN                  | 0.34 | 0.013 | 0.04 | 153 | 3.38 | 0.0015 | 0.11 | 85 |
| C1M adjusted for CRP | 0.74 | 0.0013 | 0.06 | 153 | 3.91 | <0.0001 | 0.27 | 85 |
| C1M adjusted for CRP, age, BMI and disease duration | 0.69 | 0.0022 | 0.11 | 151 | 3.60 | <0.0001 | 0.30 | 83 |
| C1M adjusted for CRP, age, BMI, disease duration and baseline JSN mTSS | 0.68 | 0.0029 | 0.11 | 151 | 3.55 | <0.0001 | 0.31 | 83 |
| C1M                  | 1.13 | 0.0035 | 0.05 | 153 | 3.40 | 0.0001 | 0.17 | 85 |
| C1M adjusted for CRP | 1.17 | 0.007 | 0.04 | 153 | 3.73 | <0.0001 | 0.25 | 85 |
| C1M adjusted for CRP, age, BMI and disease duration | 0.98 | 0.11 | 0.14 | 151 | 6.12 | <0.0001 | 0.32 | 83 |
| C1M adjusted for CRP, age, BMI, disease duration and baseline mTSS ERN | 0.95 | 0.13 | 0.14 | 151 | 6.04 | <0.0001 | 0.32 | 83 |

BMI, Body mass index; C1M, Type I collagen degraded by MMPs; CRP, C-reactive protein; ERN, erosion score; JSN, joint space narrowing; mTSS, modified total Sharp score. The regression coefficient, \( \beta \), \( P \)-value and \( R^2 \) are given. Data were log-transformed before analysis.
To further study the effect of TCZ on C1M levels, the PBO group was separated into escape and non-escape patients (Figure 2). The mean level of C1M at Week 16 was reduced by 18.2% from baseline in the non-escape patients, whereas the mean level was 1% of baseline in the escape patients. The difference in mean level of C1M between escapers and non-escapers was not significant ($P > 0.05$). The change from baseline in C1M levels was similar (approximately 6% decrease) in the escape and non-escape patients in the PBO group at Week 24, when the escape patients had been treated with 4 mg/kg TCZ + MTX for eight weeks (Figure 3B). At Week 52 the level of C1M was significantly higher ($P < 0.05$) in the non-escape patients than in the escape patients, the latter of which was treated with either 4 or 8 mg/kg TCZ (Figure 3B).

Change in C1M at 16 weeks correlated to change in radiographic measures at 52 weeks in response to TCZ

We investigated whether change in C1M after 16 weeks in response to 4 or 8 mg/kg TCZ was related to change in radiographic change after 52 weeks. We separated patients into two groups, those with less than 35% change in C1M from baseline to 16 weeks and those with more than 35% change. A significant difference was found in change in JSN after 52 weeks between the two groups ($P = 0.035$, Figure 4A). A similar difference was seen for mTSS changes ($P = 0.045$, Figure 4B). No difference in erosion was found at either 24 or 52 weeks. There was no change at 24 weeks with JSN and mTSS.

**Discussion**

RA is a complex disease in which progression is very heterogeneous and non-continuous, in which flares may be important drivers of severe progression. Selecting the patients who will benefit from a specific treatment would be an advantage in inflammatory arthritis diseases in particular, as most, if not all, anti-inflammatory treatments are associated with severe, but manageable, side effects. In this study we investigated if a novel assay detecting a protein fingerprint of type I collagen degradation could be a novel biochemical marker for identification of progressors in RA. We also investigated the change in serum C1M levels following treatment with TCZ and the predictive value of C1M in combination with CRP. We found that 1) C1M levels were associated with disease progression, 2) C1M levels were correlated

| Table 4 Odds ratios for radiographic progression when combining high and low level of C1M and CRP |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| C1M/CRP                        | High/High vs. Low/Low           | High/Low vs. Low/Low            | Low/High vs. Low/Low            | Only C1M                        |
| JSN                            | OR 3.61                        | 2.37                           | 1.95                           | 3.15                           |
| 95% CI                         | 1.62 to 8.01                   | 0.59 to 9.44                   | 0.39 to 9.77                   | 1.50 to 6.58                   |
| $P$                            | 0.0018                         | 0.22                           | 0.42                           | 0.0023                         |
| mTSS                           | OR 3.55                        | 1.79                           | 1.94                           | 2.94                           |
| 95% CI                         | 1.97 to 6.41                   | 0.60 to 5.33                   | 0.58 to 6.49                   | 1.71 to 5.05                   |
| $P$                            | <0.0001                        | 0.30                           | 0.28                           | 0.0001                         |

The high and low levels of the biomarkers were based on the median value of all patients at baseline. C1M, Type I collagen degraded by MMPs; CI, confidence interval; CRP, C-reactive protein; JSN, joint space narrowing; mTSS, modified total Sharp score; OR, odds ratio.
with disease activity at baseline, 3) baseline C1M was a significant predictor of structural progression, 4) TCZ dose-dependently inhibited the level of C1M as early as two weeks after initiating treatment, and 5) change in C1M at 16 weeks after treatment initiation was related to the level of radiographic changes over one year. The current findings contribute to the literature and the scientific field by demonstrating that quantifying specific tissue destruction may aid in selecting the RA patients in most need of aggressive treatment.

Serological biochemical markers are receiving increased attention in drug development and for guiding evidence-based patient management decisions [18]. A range of traditional markers may provide valuable in managing RA, such as CRP, ESR, and the interleukins-1 and -6. However, these markers are systemic biomarkers. A newer class of molecular biochemical markers, also assessed by simple ELISA technologies, provides independent and additional information reflecting structural changes within the tissue [5]. These markers - protein fragments - are referred to as protein fingerprints, because they are end results of specific pathological events, proteolytic degradation of, that is, the joint structure [5,6]. The protein fingerprint degradation markers of type I, II and III collagen have been studied and all three have been shown to be descriptive of disease progression and response to anti-inflammatory therapy [19]. In this study, we further show that C1M is highly correlated to CRP levels (Table 2), indicating that type I collagen degradation in RA is related to inflammation. Therefore, exploring C1M in RA will indicate the state of the specific inflammatory structural changes and not the systemic state of the inflammation. Due to the relationship between C1M and CRP, we have not investigated the difference between the biomarkers in predicting progressors of disease.

Interpreting biochemical markers found in serum is associated with many limitations, as several different tissues at different rates may produce, and thus contribute to the total pool of, the molecular marker. Type I collagen is abundant in many tissues throughout the body [5]. Bone in particular may be a prime candidate contributing to the serological C1M pool as it is naturally being constantly renewed. However, C1M has been shown not to be correlated with bone metastases, which have high and very aggressive bone resorption, and, furthermore, not to recognize MMP-3, -8 and Cathepsin K-cleaved type I collagen [13]. Thus, C1M is a biochemical marker with increased accuracy for connective tissue turnover. Other biomarkers of type I collagen degradation have previously been described in the literature in relation to RA. ICTP, a C-terminal degradation fragment of the mature type I collagen, has been shown to be related to the severity of RA [20,21] as well as disease activity [22]. It has been shown to be useful for assessing the effect of potentially disease modifying therapies [23]. ICTP in synovial fluid and serum has been shown to be correlated to radiographic measures of joint destruction [22,24]. However, RA disease duration has shown to be a cofounder in ICTP levels [25]. ICTP has also been described to be correlated to disease activity in reactive arthritis [26]. Another marker of type I collagen, CTX-I, a marker of Cathepsin K-mediated type I collagen degradation reflecting bone resorption, has previously been described to predict disease progression, albeit only in the worst quartile [27,28]. Furthermore, it has been shown in a study of early RA patients that CTX-I at baseline, adjusted for cofounders, was significantly associated with radiographic progression in the RA MRI erosion score and classical radiographs over one year [20]. A drawback of this study, however, was that there was a considerable overlap in CTX-I between progressors and non-progressors. The same group of investigators has shown that the relationship between elevated serum levels of CTX-I and subsequent joint destruction still existed at 10-year follow-up. However, the relationship was weaker [29].

In the assessment of C1M as a marker of structural progression in RA, we have utilized radiographic changes...
(JSN, mTSS and erosion score) after 24 and 52 weeks. The significance level of the correlation between C1M and radiographic scores was strongest at 52 weeks, especially with mTSS. This is due to the low sensitivity of the radiographic scores to changes in joints over a short period [30]. The low sensitivity led to high variation in scores at 24 weeks. The variation decreased when assessing the radiographic scores at 52 weeks and hence increasing the statistical power. JSN is a visualization of the space between the joints and a reduction in JSN indicates loss of cartilage and meniscal damage, hence only a part on the JSN could be associated with type I collagen, which partly could explain the lack of correlation.

A limitation of this study is the effect of concomitant intake of non-steroidal anti-inflammatory drugs and corticosteroid. These medications could have an influence on the level of C1M, but this contribution cannot be studied in this setting. Especially, prednisolone intake influences the level of inflammation and joint damage [31,32]. However, patients already take stable doses of prednisolone and/or other drugs at the time they enter the study, hence the effect of the drugs might be obliterated in the baseline measurements of C1M. Moreover, the study population of this investigation has long disease duration at baseline and profound joint damage, hence the study population is in an advanced disease stage. It is therefore not a disease population in which a biomarker of progression is needed. A study population with shorter disease duration is more ideal for this type of study. However, the disease progression of these patients is not as profound and an even larger study population would be needed. Our present study aims at identifying progressors of disease by the biomarker by which this study population is adequate, due to the rapid progression.

Conclusion
We demonstrated that a simple serum biochemical marker measurement is able to predict fast progressors in RA and we also illustrated that C1M could be used as an efficacy marker. It is critical to effectively treat tissue destructive diseases, such as RA, early to suppress inflammation and prevent destruction of the joint.

Abbreviations
BMI: body mass index; C1M: type I collagen degraded by MMPs; CRP: C-reactive protein; CTX-1: degradation product of c-terminal telopeptides of type I collagen; DAS: Disease Activity Score; ECM: extracellular matrix; ELISA: enzyme-linked immunosorbent assay; ESR: erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; JSN: joint space narrowing; MMP: matrix metalloproteinase; mTSS: modified total Sharp score; MTX: methotrexate; PBO: placebo; RA: rheumatoid arthritis; SJC: swollen joint count; TCZ: tocilizumab; TJC: tender joint count; VAS: visual analog scale.

Competing interests
ASS, ACBJ, DIL, JB and MK are full time employees at and CC and MK hold stock in Nordic Bioscience. Nordic Bioscience is a privately-owned, small- to medium-sized enterprise (SME) partly focused on the development of biomarkers for rheumatic and fibrotic diseases. None of the authors received fees, bonuses or other benefits for the work described in the manuscript. AP and DvdH declare that they have no financial or competing interests.

Authors’ contributions
ASS, ACBJ and MK did the study design. AP provided the samples. Labtechnicians at Nordic Bioscience did the C1M quantification. ASS and ACBJ did the primary data analysis, but all authors were involved in further analysis, interpretation and discussion of data. All authors were involved in the drafting of the article or revising it critically for important intellectual content and all authors approved the final version to be published.

Acknowledgements
We would like to thank all the LITHE investigators for the sublime work on recruiting patients and collecting samples for the study. We would like to acknowledge Kathrine Marcher-Mikkelsen and Blundine Dumont for the laboratory work on the biochemical markers. The LITHE study was supported by Hoffmann-La Roche and the investigation of C1M of the LITHE biomarker study was supported by the Danish Research Foundation.

References
1. Lee EG, Lee SL, Chae HJ, Park SJ, Lee YC, Yoo WH: Ethyl acetate fraction from Cudrania tricuspidata inhibits IL-1beta-induced rheumatoid synovial fibroblast proliferation and MMPs, COX-2 and PGE2 production. Biol Res 2010, 43:225-231.
2. Kim KS, Choi HM, Lee YA, Choi IA, Lee SH, Hong SJ, Yang HI, Yoo MC: Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int 2011, 31:543-547.
3. Konttinen YT, Ainaola M, Vallela H, Ma J, Ida H, Mandelin J, Kirne RW, Santavirta S, Sorsa T, Lopez-Otin C, Takagi M: Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999, 58:691-697.
4. Noss EH, Chang SK, Watts GF, Brenner MB: Modulation of matrix metalloproteinase production by rheumatoid arthritis synovial fibroblasts after cadherin 11 engagement. Arthritis Rheum 2011, 63:3768-3778.
5. Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, Bay-Jensen AC, Smith V, Adamkewicz J, Christiansen C, Leeming DJ: Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 2013, 11:70-92.
6. Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vasiadias E, Bay-Jensen AC: Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers—are they the cause or the consequence of the disease? Clin Biochem 2010, 43:793-804.
7. Carrero P, Femrmas M, Karsdal MA, Nicamhlabib B, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Dalälst J: The type I collagen frames ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003, 18:859-867.
8. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L: Radioimmunoassay for the pyridoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993, 39:635-640.
9. Melkio K, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jakkola A, Risteli J: Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996, 42:947-954.
10. Koivula MK, Richardson J, Leino A, Vallela K, Griffiths K, Barnes A, Konttinen YT, Garrity M, Risteli J: Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay. Clin Biochem 2010, 43:1453-1457.

11. Orum O, Hansen M, Jensen CH, Sørensen HA, Jensen LB, Hasslev-Petersen K, Teisner B: Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996, 19:157-163.

12. Garmo P, Vergnaud P, Hoyle N: Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008, 54:188-196.

13. Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, Koizumi M, Segovia-Silvestre T, Zhang C, Zheng G, Sun S, Cao Y, Barkholt V, Hägglund P, Bay-Jensen A, Qvist P, Karsdal M: A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP-generated type I collagen neo-epitope (C1M). Biomarkers 2011, 16:616-628.

14. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs B, Fleischmann R: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011, 63:609-621.

15. Smolen JS, Avila JC, Aletaha D: Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012, 71:687-693.

16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.

17. Genant HK, Jiang Y, Petetry C, Lu Y, Reden J, Countryman PJ: Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998, 41:1583-1590.

18. Kandal MA, Henrikson K, Leeming DJ, Mitchell P, Duffin K, Baraciu C, Krickstein L, Argyroulis P, Nemirovsky V, Björklund I, Qvist P, Bay-Jensen AC, Dam EB, Madsen SH, Christiansen C: Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarker 2009, 14:161-169.

19. Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, Karsdal MA: Ankylosing spondylitis is characterized by an increased turnover of several different metalloprotease-derived collagen species: a cross-sectional study. Rheumatol Int 2012, 32:5565-5572.

20. Syversen SW, Gaarder PI, Odegård S, Veidal S, Karsdal MA: Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996, 19:157-163.

21. Smolen JS, Avila JC, Aletaha D: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011, 63:609-621.

22. Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, Koizumi M, Segovia-Silvestre T, Zhang C, Zheng G, Sun S, Cao Y, Barkholt V, Hägglund P, Bay-Jensen A, Qvist P, Karsdal M: A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP-generated type I collagen neo-epitope (C1M). Biomarkers 2011, 16:616-628.

23. Syversen SW, Gaarder PI, Odegård S, Veidal S, Karsdal MA: Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996, 19:157-163.

24. Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, Karsdal MA: Ankylosing spondylitis is characterized by an increased turnover of several different metalloprotease-derived collagen species: a cross-sectional study. Rheumatol Int 2012, 32:5565-5572.

25. Smolen JS, Avila JC, Aletaha D: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011, 63:609-621.

26. Kotaniemi A, Risteli J, Aho K, Hakala M: Increased type I collagen degradation correlates with disease activity in reactive arthritis. Clin Exp Rheumatol 2003, 21:95-98.

27. Landewe RB, Geusens P, van der Heijde DM, Boers M, van der Linden S, Garmo P: Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis. Ann Rheum Dis 2006, 65:40-44.

28. Garmo P, Landewe R, Boers M, Verhoeven A, Van Der Linden S, Christgau S, Van Der Heijde D, Boonen A, Geusens P: Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002, 46:2847-2856.

29. Syversen SW, Goll GL, van der Heijde D, Landewe R, Gaarder PI, Odegård S, Haavardsholm EA, Kien TK: Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol 2009, 36:266-272.

30. Sokka T: Radiographic scoring in rheumatoid arthritis: a short introduction to the methods. Bull NYU Hosp Jt Dis 2008, 66:166-168.

31. Hafstrøm I, Albertsson K, Boonen A, van der Heijde D, Landewe R, Svensson B, BARFOT Study Group: Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 2009, 68:508-513.

32. van Tuyl LH, Boers M, Lems WF, Landewe RB, Han H, van der Linden S, van de Laar M, Westhovens R, van Denderen JC, Westedt ML, Peeters AJ, Jacobs P, Huzinga TW, van de Brink H, Dijkmans BA, Voiskuyl AE: Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010, 69:907-912.

Cite this article as: Siebuhr et al. Serological identification of fast progresors of structural damage with rheumatoid arthritis. Arthritis Research & Therapy 2013 15:R86.

doi:10.1186/ar4266

Submit your next manuscript to BioMed Central
and take full advantage of:

• Convenient online submission
• Thorough peer review
• Convenient online submission
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit